Beneficial effects of intracoronary tirofiban bolus administration following upstream intravenous treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: The ICT-AMI study

International Journal of Cardiology

Volumn 165, Issue 3, 2013, Pages 437-443

  Zhu, Tian Qi ^a   Zhang, Qi ^a   Qiu, Jian Ping ^b   Jin, Hui Geng ^c   Lu, Lin ^a   Shen, Jie ^a   Zhao, Liang Ping ^a   Zhang, Rui Yan ^a   Hu, Jian ^a   Yang, Zhen Kun ^a   Shen, Wei Feng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Gongli Hospital   (China)

^c Department of Medical Imaging   (China)

Author keywords

Angiography; Electrocardiogram; Glycoprotein IIb IIIa inhibitor; Myocardial infarction; Outcome; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID A PROTEIN; CD40 LIGAND; CLOPIDOGREL; PADGEM PROTEIN; TIROFIBAN; VON WILLEBRAND FACTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY SINUS; FEMALE; FOLLOW UP; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART MUSCLE REPERFUSION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVAL RATE; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; HEART LEFT VENTRICLE VOLUME; INFLAMMATION; INTRACORONARY DRUG ADMINISTRATION; THROMBOCYTE ACTIVATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY;

AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRA-ARTERIAL; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TREATMENT OUTCOME; TYROSINE;

EID: 84877027218     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.08.082     Document Type: Article

References (31)

1. J. Figueras, I. Ferreira-Gonzalez, and M. Rizzo High incidence of TIMI flow 0 to I in patients with ST-elevation myocardial infarction without electrocardiographic lytic criteria Am Heart J 158 2009 1011 1017
2. F.G. Kushner, M. Hand, and S.C. Smith Jr. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 120 2009 2271 2306
3. F. Van de Werf, J. Bax, and A. Betriu Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the management of ST-segment elevation acute myocardial infarction of the European society of cardiology Eur Heart J 29 2008 2909 2945
4. M.L. Fokkema, P.J. Vlaar, and T. Svilaas Incidence and clinical consequences of distal embolization on the coronary angiogram after percutaneous coronary intervention for ST-elevation myocardial infarction Eur Heart J 30 2009 908 915
5. W. Hochholzer, D. Trenk, and D. Frundi Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention Circulation 111 2005 2560 2564
6. S. Goto, N. Tamura, and H. Ishida Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions J Am Coll Cardiol 44 2004 316 323
7. T. Heestermans, A.W.J. van 't Hof, and J.M. ten Berg The golden hour of prehospital reperfusion with triple antiplatelet therapy: a sub-analysis from the ongoing Tirofiban in Myocardial Evaluation 2 (On-TIME 2) trial early initiation of triple antiplatelet therapy Am Heart J 160 2010 1079 1084
8. J. Shen, Q. Zhang, and R.Y. Zhang Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention Coron Artery Dis 19 2008 271 277
9. T. Rakowski, Z. Siudak, and A. Dziewierz Early abciximab administration before transfer for primary percutaneous coronary interventions for ST-elevation myocardial infarction reduces 1-year mortality in patients with high-risk profile. Results from EUROTRANSFER registry Am Heart J 158 2009 569 575
10. Y.L. Gu, M.A. Kampinga, and W.G. Wieringa Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial Circulation 122 2010 2709 2717
11. A.J. Deibele, L.K. Jennings, and J.E. Tcheng Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial Circulation 121 2010 784 791
12. P.R. Hansen, A. Iversen, and J. Abdulla Improved clinical outcomes with intracoronary compared to intravenous abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a systematic review and meta-analysis J Invasive Cardiol 22 2010 278 282
13. E.J. Topol, T.V. Byzova, and E.F. Plow Platelet GPIIb-IIIa blockers Lancet 353 1999 227 231
14. G.B. Danzi, C. Capuano, and M. Sesana Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb/IIIa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention Am J Cardiol 97 2006 489 493
15. N.M. Ernst, H. Suryapranata, and K. Miedema Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction J Am Coll Cardiol 44 2004 1187 1193
16. R.H. Aster, B.R. Curtis, and D.W. Bougie Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors J Thromb Haemost 4 2006 678 679
17. P.A. Merlini, M. Rossi, and A. Menozzi Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting Circulation 109 2004 2203 2206
18. M. Valgimigli, G. Campo, and G. Percoco Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial JAMA 299 2008 1788 1799
19. J.L. Januzzi Jr., S.M. Snapinn, and P.M. DiBattiste Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial Circulation 105 2002 2361 2366
20. R.Y. Zhang, Z.B. Zhu, and Q. Zhang Impact of moderate or severe renal insufficiency on long-term outcomes in patients undergoing drug-eluting stent based coronary intervention Int J Cardiol 136 2009 72 79
21. K. Huber, D.R. Holmes Jr., and A.W. van 't Hof Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial Eur Heart J 31 2010 1708 1716
22. A.K. Rao, C. Pratt, and A. Berke Thrombolysis in Myocardial Infarction (TIMI) Trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase J Am Coll Cardiol 11 1988 1 11
23. M. Napodano, A. Ramondo, and G. Tarantini Predictors and time-related impact of distal embolization during primary angioplasty Eur Heart J 30 2009 305 313
24. S. Matetzky, B. Shenkman, and V. Guetta Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 2004 3171 3175
25. H. Thiele, K. Schindler, and J. Friedenberger Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial Circulation 118 2008 49 57
26. C.M. Gibson, C. Zorkun, and V. Kunadian Intracoronary administration of abciximab in ST-elevation myocardial infarction Circulation 118 2008 6 8
27. H.D. White, R.M. Norris, and M.A. Brown Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction Circulation 76 1987 44 51
28. Y.J. Yang, J.L. Zhao, and S.J. You Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion Heart 92 2006 1131 1137
29. W. Maier, L.A. Altwegg, and R. Corti Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein Circulation 111 2005 1355 1361
30. B.G. Angeja, M. Gunda, and S.A. Murphy TIMI myocardial perfusion grade and ST segment resolution: association with infarct size as assessed by single photon emission computed tomography imaging Circulation 105 2002 282 285
31. M. Sejersten, N. Valeur, and P. Grande Long-term prognostic value of ST-segment resolution in patients treated with fibrinolysis or primary percutaneous coronary intervention results from the DANAMI-2 (DANish trial in acute myocardial infarction-2) J Am Coll Cardiol 54 2009 1763 1769